Immunotherapeutic implications of the immunophenotype of pediatric brain tumors

OncoImmunology

Volumn 3, Issue 1, 2014, Pages

  Griesinger, Andrea M ^a,b   Donson, Andrew M ^a,b   Foreman, Nicholas K ^a,b  

^a University of Colorado Denver and Children s Hospital Colorado   (United States)

^b CHILDREN S HOSPITAL COLORADO   (United States)

Author keywords

Flow cytometry; Immune cell characterization; Immunotherapy; Pediatric brain tumor

Indexed keywords

CANCER ANTIBODY; CD163 ANTIGEN; CD206 ANTIGEN; CD64 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GANGLIOSIDE GD2; HLA DR ANTIGEN; LYMPHOCYTE ANTIGEN; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; BRAIN TUMOR; CANCER CLASSIFICATION; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL INFILTRATION; CHILDHOOD CANCER; CYTOFLUOROMETRY; DENDRITIC CELL; DRUG EFFICACY; EPENDYMOMA; EPILEPSY; GLIOBLASTOMA; GLIOMA; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; MEDULLOBLASTOMA; NEUROBLASTOMA; NEUROECTODERM TUMOR; PASSIVE IMMUNIZATION; PERSONALIZED MEDICINE; PHASE 3 CLINICAL TRIAL (TOPIC); PILOCYTIC ASTROCYTOMA; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

EID: 84899088902     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27256     Document Type: Article

References (10)

1. Griesinger AM, Birks DK, Donson AM, Amani V, Hoffman LM, Waziri A, Wang M, Handler MH, Foreman NK. Characterization of distinct immunophenotypes across pediatric brain tumor types. J Immunol 2013; 191:4880-8; PMID:24078694; http://dx.doi.org/10.4049/jimmunol.1301966.
2. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, et al.; Children's Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363:1324-34; PMID:20879881; http://dx.doi.org/10.1056/NEJMoa0911123.
3. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6:443-6; PMID:10742152; http://dx.doi.org/10.1038/74704.
4. Donson AM, Birks DK, Barton VN, Wei Q, Kleinschmidt-Demasters BK, Handler MH, Waziri AE, Wang M, Foreman NK. Immune gene and cell enrichment is associated with a good prognosis in ependymoma. J Immunol 2009; 183:7428-40; PMID:19917695; http://dx.doi.org/10.4049/jimmunol.0902811.
5. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23:2346-57; PMID:15800326; http://dx.doi.org/10.1200/JCO.2005.00.240.
6. Ardon H, De Vleeschouwer S, Van Calenbergh F, Claes L, Kramm CM, Rutkowski S, Wolff JE, Van Gool SW. Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediatr Blood Cancer 2010; 54:519-25; PMID:19852061.
7. Caruso R, Wierzbicki V, Marrocco L, Salvati M. Paragangliomas of the cauda equina. Report of one case and review of the literature. J Exp Clin Cancer Res 2006; 25:269-75; PMID:16918140.
8. Peres E, Wood GW, Poulik J, Baynes R, Sood S, Abidi MH, Klein J, Bhambhani K, Dansey R, Abella E. High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors. Neuropediatrics 2008; 39:151-6; PMID:18991194; http://dx.doi. org/10.1055/s-0028-1093333.
9. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-44; PMID:23724846; http://dx.doi. org/10.1056/NEJMoa1305133.
10. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466.